Treprostinil Dry Powder Inhaler (treprostinil)-Yutrepia is a medicine that treats what

Treprostinil dry powder inhalation (treprostinil)-Yutrepia is a prostacyclin mimetic mainly used to treat pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension associated with interstitial lung disease (PH-ILD). The drug is designed to enhance drug deposition in the lungs via inhalation, thereby improving efficacy.

Indications for Yutrepia include:

1. Pulmonary arterial hypertension (PAH): According to the classification of the World Health Organization, PAH belongs to Group 1 disease. Yutrepia can be used to improve patients' exercise capacity, especially in patients with NYHA functional class III. Of these patients, 56% had idiopathic or hereditary pulmonary hypertension, and 33% were associated with connective tissue diseases.

2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD): PH-ILD belongs to World Health Organization Group 3, and the use of Yutrepia can improve exercise capacity. Efficacy studies involved patients with idiopathic interstitial pneumonia (45%), including patients with primary pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and patients with connective tissue disorders (22%).

Pulmonary hypertension is a rare and progressive disease caused primarily by narrowing, thickening, or hardening of the pulmonary arteries that, if left untreated, may lead to right heart failure and death. Pulmonary hypertension related to interstitial lung disease includes a variety of lung diseases, such as interstitial pulmonary fibrosis and chronic hypersensitivity pneumonitis. Common symptoms include shortness of breath, chest tightness, increased heart rate, and edema of the lower limbs.

Yutrepia contains treprostinil, an ingredient approved by the U.S. Food and Drug Administration (FDA) in 2002. Treprostinil is marketed under a variety of brands and dosage forms, including injections, inhalation solutions, inhalation powders, and extended-release tablets. Yutrepia's FDA approval is based on results from the Phase 3 INSPIRE trial, which demonstrated its safety and tolerability in patients who have not been previously exposed to treprostinil.

Reference materials:https://www.drugs.com/pro/yutrepia.html